Brief: Aelis Farma Announces The Results Of Its Clinical Phase 2B Study With Aef0117

Aelis Farma SA

04/09/2024 06:03

Sept 4 (Reuters) - Aelis Farma SA  AELIS.PA :
    * AELIS FARMA ANNOUNCES THE RESULTS OF ITS CLINICAL PHASE 2B
STUDY
WITH AEF0117, AMONG PARTICIPANTS WITH CANNABIS USE DISORDER
(CUD)
    * AELIS FARMA SA - AEF0117 WAS WELL TOLERATED, AND NO SAFETY
CONCERNS WERE IDENTIFIED
    * AELIS FARMA SA - PRIMARY AND SECONDARY ENDPOINTS WERE NOT
MET BY
AEF0117
    * AELIS FARMA SA  - IS INVESTIGATING THESE QUANTITATIVE
IMPROVEMENTS FURTHER IN ORDER TO DETERMINE BEST COURSE OF
STRATEGIC AND REGULATORY ACTIONS

Source text for Eikon:  ID:nBw8Nw1rWa 
Further company coverage:  AELIS.PA 

 ((Reuters.Briefs@thomsonreuters.com;))